MLPA vs ddPCR vs qPCR vs NGS for CNV (RUO): Technical Comparison and Decision Framework

Copy number variation (CNV) projects often go off track because teams compare platforms before they define the technical question. In research-use-only (RUO) workflows, the best method is rarely the one with the biggest platform footprint. It is the one that matches target count, output type, sample constraints, analysis burden, and the way results will move across wet lab, bioinformatics, and project management. The core split is straightforward: MLPA is designed for multiplex relative copy-number screening across many predefined loci, qPCR is usually a better fit for one or a few loci, ddPCR is strongest when absolute copy-number focus matters, and NGS becomes attractive when broader context or discovery is part of the scope.

TL;DR — Choose Your CNV Method in 60 Seconds

Choose qPCR when the question is narrow, the target list is small, and a relative dosage answer is enough. qPCR remains useful for focused CNV checks, but its reproducibility depends heavily on assay design, reference choice, and transparent reporting practice.

Choose ddPCR when the project centers on absolute copy number and on distinguishing nearby copy-number states with stronger statistical separation. Partition-based digital PCR was developed for absolute DNA copy-number quantitation and is widely used when precision matters more than multiplex breadth.

Choose MLPA when you need many predefined loci in parallel, especially exon-level or region-level screening without a need for broad sequence context. The original MLPA paper demonstrated relative quantification of up to 40 sequences in one reaction, which is why MLPA still maps well to many-locus targeted CNV workflows.

Choose NGS when CNV is only one layer of a broader sequencing question, or when the project needs additional sequence context. Recent large benchmarks show that NGS-based CNV calling from targeted panels can be highly informative, but performance still depends on data context, caller choice, and parameterization.

If you need a fundamentals refresher before the comparison, start with What is MLPA (meaning/definition/principle).

Four-Method Comparison at a Glance

This table is the shortest workable summary of the decision logic used throughout the rest of the article: target count, absolute need, sequence context, and analysis burden should be defined before a method is shortlisted.

Define the Technical Requirements First

Before comparing platforms, define the project in four practical dimensions.

1) How many loci are in scope?

This is the first real branch. qPCR is manageable for a small number of loci, but each added target increases design and control burden. MLPA was built to make many predefined loci practical in a single assay. NGS can cover much more space, but that gain in breadth comes with more library, analysis, and review overhead.

In outsourcing terms, a two-locus project across hundreds of samples is not the same as a 30- to 40-region project across the same cohort. Teams evaluating CNV sequencing services should define target-space complexity before they discuss timeline or deliverables.

2) Do you need relative dosage or absolute copies?

MLPA and most qPCR CNV workflows are relative by design. ddPCR is attractive when absolute copy-state focus matters, because digital partitioning reduces dependence on amplification-curve interpretation. That difference is often more important than generic claims about "accuracy."

3) Do you need broader sequence context?

If the project only needs copy-number information at known loci, targeted methods can be operationally cleaner. If it also needs broader surrounding context, discovery, or integration with broader sequencing outputs, NGS moves up the shortlist. Recent benchmarking on panel data also makes clear that computational CNV calling is not context-free; performance varies with tools, datasets, and parameters.

4) How much analysis burden can the team absorb?

qPCR can look simple but still fail through poor assay design or unstable references. MLPA is efficient at the assay level but depends strongly on peak quality and normalization discipline. NGS offers the widest context but places the heaviest load on pipeline selection, reference matching, and technical review. Transparent reporting guidance such as MIQE and MIQE 2.0 is relevant because reproducibility depends on experimental detail, not only on platform choice.

Figure 1. CNV Method Selection Map: define target count, absolute-copy need, sequence-context need, and analysis burden before choosing a method.

MLPA vs qPCR for CNV

MLPA and qPCR are often compared because both can answer targeted CNV questions, but they scale differently.

Multiplexing and design burden

MLPA's core advantage is multiplexing across many predefined loci in one assay. qPCR remains practical for a very small number of loci, but every additional locus adds primer/probe design work, more control dependence, and more opportunities for efficiency-related drift. That is why the question is not whether qPCR can detect a CNV, but whether it remains the best workflow once the design expands beyond a few loci.

If the project is drifting toward many predefined exons or regions, Gene Panel Sequencing Service may become a more natural adjacent option for teams that also want broader target architecture in the same program.

Normalization dependence and failure modes

qPCR depends heavily on reference stability, assay efficiency, and sample quality. The MIQE literature exists because those details materially affect reproducibility. Two especially relevant qPCR pitfalls for CNV are sample degradation and variants inside reference-assay binding regions, both of which can distort apparent copy number.

MLPA has a different risk profile. Once the assay design fits the target space, its main vulnerabilities shift toward ligation behavior, fragment separation, peak quality, and normalization. In practice, qPCR tends to concentrate risk in assay/reference behavior, while MLPA concentrates risk in signal-quality and normalization review.

Practical decision rule

Use qPCR when you have very few targets, need fast relative readout, and can tightly control assay design and references. Use MLPA when you have many predefined regions and need efficient parallel screening with a disciplined QC workflow. For teams planning a formal MLPA workflow, MLPA test & assay workflow: sample requirements + deliverables is the most useful next read.

Figure 2. MLPA vs qPCR technical comparison grid covering multiplexing, design burden, normalization dependence, throughput, and interpretation style.

MLPA vs ddPCR for CNV

This is usually the most important comparison when the team wants more confidence than qPCR but is unsure whether the project needs multiplex breadth or absolute copy focus.

Relative multiplex screening vs absolute quantification

MLPA is a multiplex relative method. ddPCR is an absolute-copy-oriented method based on partitioning. If the uncertainty is spread across many predefined exons or regions, MLPA is often the better fit. If the uncertainty is concentrated in one or a few loci and exact copy-state separation matters, ddPCR becomes the stronger option.

Throughput and scaling

ddPCR is excellent for precision, but it does not solve multi-locus scaling in the same way MLPA does. A few high-priority loci across many samples may fit ddPCR well. A broad exon-level screen across many samples usually maps more naturally to MLPA. This is why the choice is often driven by locus complexity, not by abstract claims that one technology is "more accurate."

Follow-up workflows

Many RUO programs should not force a single method to answer every question. One practical pattern is broad targeted screening first, then additional technical characterization on a smaller subset of loci. Another is NGS first, then targeted locus-level follow-up once the broad sequence picture is clearer. That staged logic is often more robust than expecting one platform to deliver both breadth and exactness at once. For targeted follow-up planning, Targeted Region Sequencing is often the most relevant adjacent service page.

For CNV-specific study planning and output review, see MLPA for CNV: study design & interpretation.

MLPA vs NGS for CNV

This is the comparison most often overstated. NGS is not an automatic upgrade over MLPA. It answers a broader class of questions.

When NGS is the better fit

NGS becomes attractive when CNV is only one layer of a larger sequencing workflow, or when sequence context matters enough to justify heavier downstream analysis. Current large-scale benchmarking shows that panel-derived CNV calling can work well, but tool behavior still varies, especially for smaller events and parameter-sensitive settings.

When MLPA remains the better fit

If the project already knows the loci of interest and the key task is efficient region-level copy-number screening, MLPA can remain the cleaner technical choice. That is especially true when sequence context is not the core deliverable and when teams value a narrower review surface over a broader computational pipeline. Teams leaning toward broader discovery can evaluate Whole Exome Sequencing as the more relevant service path.

Where "MLPA Analysis" Can Make or Break Confidence

MLPA is efficient at the assay level, but it is unforgiving of weak review discipline. This is where many comparison articles stay too general.

Good MLPA confidence depends on stable peak profiles, appropriate references, consistent normalization, and explicit handling of borderline ratios. The assay may be the right one, yet the project can still fail if QC gates are vague or report logic is inconsistent. That is why MLPA vendor evaluation should include how raw signals are reviewed, how repeats are triggered, and how borderline regions are categorized.

A practical troubleshooting frame is useful:

• Noisy or unstable peak patterns usually point to input-quality variability, ligation inconsistency, or normalization problems.
• Isolated region shifts often require raw-trace review before they are treated as meaningful.
• Cross-method discrepancies often reflect different output types being compared as if they were equivalent, rather than a simple "right versus wrong" situation.

For deeper QC and report structure, see MLPA analysis QC + normalization + report checklist.

Final Decision Framework

Use this checklist in kickoff meetings, vendor review, or sample-submission planning.

• 1. Are we measuring one/few loci or many predefined loci?
• 2. Do we need relative dosage or absolute copies?
• 3. Do we need broader sequence context?
• 4. Is this a broad screen or a narrow high-confidence follow-up workflow?
• 5. How variable is DNA quantity or integrity?
• 6. Can the team support assay-design iteration?
• 7. Can the team support sequencing-style analysis burden?
• 8. Does multiplex breadth matter more than absolute copy precision?
• 9. What repeat rate is operationally acceptable?
• 10. Will a staged workflow be more efficient than a one-platform workflow?

Map the answers like this:

• MLPA fits many predefined loci and efficient parallel screening.
• qPCR fits one or a few loci with a simple relative readout.
• ddPCR fits absolute-copy-focused projects with low target count.
• NGS fits broader context or discovery-oriented projects.

Figure 3. Four-way CNV decision tree covering qPCR, ddPCR, MLPA, and NGS, aligned to target count, absolute-copy need, sequence-context need, and analysis burden.

FAQ

Is MLPA more suitable than qPCR for exon-level CNV screening?

Usually yes when many predefined regions must be assessed in parallel, because MLPA was designed for multiplex relative quantification across many loci. qPCR remains more natural when the project is limited to one or a few loci.

When is ddPCR worth the extra effort?

When the project specifically needs absolute copy-state focus or stronger discrimination between nearby copy-number states. That is the context where digital partitioning adds the most value.

Can NGS replace MLPA?

Sometimes, but not by default. If the project already needs broader sequencing context, NGS may be the more efficient umbrella workflow. If it only needs predefined region-level CNV screening, MLPA may still be the cleaner choice.

What is the hidden risk in qPCR CNV work?

Reference dependence. Poor reference choice, degraded DNA, or variation inside a reference assay can distort apparent copy number.

What is the hidden risk in MLPA work?

Treating normalization and peak review as routine. MLPA confidence depends heavily on QC discipline and consistent interpretation rules.

What should outsourcing teams ask a provider before choosing a CNV method?

Ask how the provider handles sample QC, repeat criteria, normalization logic, borderline calls, and staged follow-up workflows when one method is not enough. Those answers often matter more than the platform list alone.

References:

1. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Research. 2002;30(12):e57. DOI:10.1093/nar/gnf056
2. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clinical Chemistry. 2009;55(4):611-622. DOI:10.1373/clinchem.2008.112797
3. Bustin SA, Huggett JF, Vandesompele J, Wittwer CT, et al. MIQE 2.0: Revision of the Minimum Information for Publication of Quantitative Real-Time PCR Experiments Guidelines. Clinical Chemistry. 2025;71(6):634-651. DOI:10.1093/clinchem/hvaf043
4. Hindson BJ, Ness KD, Masquelier DA, et al. High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number. Analytical Chemistry. 2011;83(22):8604-8610. DOI:10.1021/ac202028g
5. Cukier HN, Pericak-Vance MA, Gilbert JR, Hedges DJ. Sample degradation leads to false-positive copy number variation calls in multiplex real-time polymerase chain reaction assays. Analytical Biochemistry. 2009;386(2):288-290. DOI:10.1016/j.ab.2008.11.040
6. Sicko RJ, Romitti PA, Browne ML, Brody LC, Stevens CF, Mills JL, Caggana M, Kay DM. Rare Variants in RPPH1 Real-Time Quantitative PCR Control Assay Binding Sites Result in Incorrect Copy Number Calls. The Journal of Molecular Diagnostics. 2022;24(1):33-40. DOI:10.1016/j.jmoldx.2021.09.007
7. Munté E, Roca C, del Valle J, et al. Detection of germline CNVs from gene panel data: benchmarking the state of the art. Briefings in Bioinformatics. 2025;26(1):bbae645. DOI:10.1093/bib/bbae645